P
NBIX icon

&Partners’s Neurocrine Biosciences NBIX Stock Holding History

&Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Buy
1,820
+8
+0.4% +$1.06K ﹤0.01% 2140
2025
Q4 		$257K Buy
1,812
+125
+7% +$18.1K ﹤0.01% 2008
2025
Q3 		$237K Sell
1,687
-47
-3% -$6.37K ﹤0.01% 1878
2025
Q2 		$218K Buy
+1,734
New +$199K ﹤0.01% 1793

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

&Partners's NBIX Position: Q1 2026 in Review

&Partners increased its Neurocrine Biosciences (NBIX) stake by 0.44% in Q1 2026, buying an estimated $1.06K and bringing the position to 1,820 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

&Partners first reported a position in NBIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $257K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • &Partners held 1,820 shares of Neurocrine Biosciences worth $240K as of Q1 2026.
  • &Partners bought 8 Neurocrine Biosciences shares in Q1 2026, an estimated $1.06K.
  • Neurocrine Biosciences made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2140 holding.
  • &Partners first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 4 quarters since.
  • &Partners's Neurocrine Biosciences position peaked at $257K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.